Articles tagged with Clinical Trials
A post hoc analysis of the Finerenone Trial reveals that sudden death in heart failure was often preceded by modest worsening of symptoms and declining quality of life. The study suggests limited specificity for sudden death among other modes of death, implying a complex trajectory before modes of death.
A clinical trial found that intensive cholesterol-lowering therapy reduced the risk of cardiovascular events by 31% in high-risk patients with diabetes. The treatment, evolocumab, lowered LDL-C levels by approximately 60%, and was well-tolerated.
The FDA has approved a gene therapy for severe leukocyte adhesion deficiency-I, a rare genetic condition that affects one in a million children globally. The therapy, Kresladi, has been shown to significantly reduce severe infections and improve immune function in treated patients.
Dr. Emily Lukacz has been named the 2026 President of American Urogynecologic Society, a prestigious position that recognizes her innovative leadership in the complex field of urogynecology. As president, she aims to streamline treatment by educating primary care providers and allied health professionals.
The phase III Alliance ATOMIC trial shows that adding immunotherapy to standard chemotherapy improves clinical outcomes for patients with stage III dMMR colon cancer. The study found a 50% reduction in cancer recurrence risk and a 86.3% disease-free survival rate at three years.
A multi-phase clinical study will examine dosing, safety and long-term effects of rapamycin in older adults to guide future research on extending health span. Researchers aim to establish evidence-based guidance for the drug's use and move beyond speculation.
A global panel of experts recommends a 10-year trial with 5,000 participants at high risk of cancer due to pre-cursor conditions. The trial will evaluate the potential efficacy of GLP-1 and dual receptor agonists in preventing obesity-related cancers.
The Linda and Mike Mussallem Foundation has donated to USC's Keck School of Medicine to enhance clinical trials for individuals with Down syndrome at risk for Alzheimer's. This will increase domestic and international sites, accelerating the development of treatments specifically for this population.
A new Australian study shows that a tailored, home-based program can significantly reduce the number of falls after stroke. The 'falls after stroke trial' (FAST) found that the program reduced falls by 33% over 12 months.
A multicenter randomized clinical trial found no significant differences in cognitive improvement between exercise, intensive pharmacological reduction of cardiovascular risk factors, or both in older adults. The study results challenge current recommendations on lifestyle modifications for dementia prevention.
Southwest Research Institute's new facility supports pharmaceutical development, bioengineering research, and streamlined clinical supply production. The facility enhances regulatory efficiency, quality systems, and communication between scientists.
The largest behavioral study on kidney stone prevention tested a hydration program with Bluetooth-enabled smart water bottles and personalized hydration goals. While participants did hydrate more, the increase wasn't large enough to lower symptomatic kidney stone recurrence across the group.
Dr. Ludwig Kappos has made enormous contributions to MS research, advancing clinical trial conduct and outcome measures, and leading international collaborations. He will formally receive the award at the American Academy of Neurology Annual Meeting in Chicago on April 19, 2026.
The ECOG-ACRIN Cancer Research Group has completed enrollment of 600 patients in the phase 2/3 trial EA6141, evaluating dual checkpoint blockade with nivolumab and ipilimumab plus sargramostim for unresectable stage 3 or 4 melanoma. The trial aims to assess overall survival, progression-free survival, and treatment tolerability.
The Robert A. Winn Excellence in Clinical Trials Award Program is expanding its career development award to include neuropsychiatry researcher-physicians. This expansion aims to improve clinical trial enrollment and represent diverse patient populations affected by complex disorders.
A randomized clinical trial investigated the effectiveness of low-use vs high-use physical restraint strategies in critically ill patients receiving mechanical ventilation in the ICU. The study found no significant reduction in days free of delirium or coma at 14 days, regardless of the restraint strategy used.
Researchers at Université catholique de Louvain discovered a bacterium, Dolosigranulum pigrum, that reduces the persistence of symptoms characteristic of long Covid. The study found that this bacterium is associated with improved recovery following viral respiratory infections.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
A clinical trial found that weekly injectable extended-release buprenorphine treatment resulted in higher rates of illicit opioid abstinence during pregnancy compared to sublingual buprenorphine. Serious adverse events were also less common in the extended-release group.
Continuing GLP-1/GIP agonists before upper endoscopy increased clinically significant residual gastric volume, but did not elevate adverse event risk. Clear liquids the day prior to the procedure may mitigate this risk.
A new smartphone app has been shown to significantly improve sex life and delay ejaculation in men with premature ejaculation. The app, developed by urologists and psychologists, teaches men therapeutic techniques and exercises to manage arousal and control ejaculation.
Researchers evaluated 12 hypnotic medications on sleep architecture and respiratory function in adults with obstructive sleep apnea. The study found that while some medications worsened respiratory outcomes, others showed no significant effects, highlighting the need for individualized treatment.
The ISSCR has launched a new continuing education course on stem cell therapies for Parkinson’s disease, addressing the need for clinicians to provide accurate information on emerging treatments. The course features expert faculty and patient perspectives, and is available through a free and paid pathway.
A phase 3 clinical trial by Mass General Brigham reveals romiplostim's ability to prevent chemotherapy-induced thrombocytopenia, allowing full-dose chemotherapy delivery. The medication boosts bone marrow's resistance to chemotherapy, reducing the risk of life-threatening bleeding and improving cancer treatment outcomes.
A new study suggests that using virtual reality (VR) to explain medical procedures can help patients better understand their treatment and reduce anxiety. The research tested VR as part of the consent process for a procedure to treat kidney stones, with patients reporting improved understanding and reduced anxiety after the experience.
A new imaging test, PSMA PET/CT scan, has been shown to safely reduce the number of biopsies needed for suspected prostate cancer, with no harm to patients. The PRIMARY2 trial found that the scan could identify low-risk patients who did not need a biopsy, while targeting suspicious areas for those who did.
Genethon's GNT0004 gene therapy shows long-term efficacy in patients with Duchenne muscular dystrophy, maintaining clinical efficacy and safety at two years. The trial included 72 boys aged 6-10 with retained walking ability, treated with GNT0004 at a therapeutic dose.
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
The Butantan-DV dengue vaccine, developed in Brazil, shows 80.5% effectiveness against severe cases over five years, with no hospitalizations in the vaccinated group. The vaccine was 65% effective in preventing symptomatic dengue during the five-year monitoring period.
A large venous thrombosis trial has found that apixaban is safer than rivaroxaban, with 3.3% of participants experiencing clinically relevant bleeding compared to 7.1% with rivaroxaban. This trial has significant implications for clinical practice and patient care.
Research presented at EAU26 confirms that prostate cancer screening leads to a reduction in mortality, but also detects cancers that would otherwise remain undetected. The study's findings suggest that using MRI in prostate cancer screening can reduce overdiagnosis and unnecessary biopsies.
A low-cost digital intervention increased expectation to adopt health behaviors among adults using GLP-1RAs, with effects persisting for 2 weeks. The written microsteps intervention plus short video boosters may play a role in promoting sustained behavior change.
The company's ATA-200 gene therapy has shown safety, pharmacodynamics, and efficacy results in the first patients treated, offering hope for children with LGMD-R5. The therapy delivers a normal copy of the γ-sarcoglycan gene and has been awarded Orphan Drug Designation in the US and Europe.
A new PET imaging study reveals that ketamine relieves treatment-resistant depression by altering AMPAR in brain regions, providing potential biomarker for personalized treatment. The study found that ketamine increased AMPAR density in several cortical regions and decreased it in reward-related areas, strongly correlating with reducti...
A study found that only 9% of older adults with advanced cancer prioritize extending survival over maintaining quality of life. The lack of responsiveness of the current oncology care delivery system to patient preference may be a significant issue. This highlights the need for care system changes to prioritize patient needs.
ISM4808, a PHD inhibitor for chronic kidney disease-related anemia, has achieved its first milestone with successful completion of the Phase I clinical trial. The treatment stimulates endogenous erythropoietin production and improves iron utilization, offering improved efficiency and safety compared to existing treatments.
Researchers investigated low-dose lithium as a potential treatment for mild cognitive impairment in a pilot clinical trial. The study found that none of the primary outcomes met the significance threshold, but effect size estimates suggest potential benefits for future trials.
New MSK research reveals that the TCA cycle's waste-management function may present an opportunity against cancer, microplastics impair immune 'housekeeping' functions and TOX plays different roles in different immune cells. A new combination approach for treating advanced kidney cancer after immunotherapy has also been identified.
Researchers analyzed 15-year data from a clinical trial, finding that 70% of patients remained alive and 42% were considered cured after treatment. Cure modeling estimated the overall cure rate at 42% of treated patients.
A new analysis shows that 42% of treated patients were functionally cured, marking a game-changer for an incurable disease. Recurrence rates declined drastically over time, from 6.8% in the first five years to 0.6% between 15 and 20 years.
Approximately 40 cancer patients will receive LMP744 for five consecutive days, with biological analyses conducted on brain tissues before and after treatment. If results are favorable, treatment will continue for 12 cycles to evaluate parameters such as progression-free survival and overall survival.
Researchers at The Hospital for Sick Children have developed new guidelines for pediatric clinical trial reporting, incorporating child and youth-focused considerations. The SPIRIT-C 2026 and CONSORT-C 2026 guidelines aim to improve the quality, transparency, and usefulness of pediatric RCT protocols and final reports.
The Barshop Institute will conduct the VITAL-H trial, evaluating the repurposing of FDA-approved medications to delay age-related health decline in generally healthy middle-aged adults. The trial aims to preserve everyday abilities during a critical window of midlife aging.
Researchers developed a blood test to predict when Alzheimer's symptoms will start, using protein p-tau217 in plasma. The models predicted the onset of symptoms with accuracy, suggesting potential for preventive treatments.
A Phase 3 trial found stereotactic radiation targeting individual tumors improved symptom burden, cognitive outcomes, and daily function compared to whole brain radiation. Patients managed with stereotactic radiation also displayed better performance status and could remain more independent with everyday activities.
The University of California San Diego School of Medicine and UC San Diego Health are now part of the NICHD Maternal-Fetal Care Network, expanding access to research on pregnancy and newborn health. Clinical trials will focus on maternal mortality, prematurity birth rates, and infant mortality rates.
A new study uses advanced MRI to accurately diagnose progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), two underdiagnosed conditions. This breakthrough enables precise clinical trials and transforms treatment options for patients with balance problems, falls, stiffness, or difficulties with speech and movement.
Researchers from UC San Francisco successfully decoded brain activity patterns associated with walking, enabling the development of personalized neural biomarkers for movement state classification. This breakthrough could lead to more effective adaptive DBS systems that adjust stimulation in response to a patient's activity state.
A study published in Biological Psychiatry identified speech latency as a promising biomarker to enrich clinical trials for patients with schizophrenia. By analyzing speech latency, participants with a high placebo response can be identified and excluded, leading to significant improvements in treatment outcomes.
A global study found that ropeginterferon alfa-2b controls essential thrombocythemia effectively, improves symptoms and reduces serious complications in patients who can't use hydroxyurea. The therapy is expected to be approved for treatment of high-risk blood cancer.
The University of Missouri has launched its first human clinical trial using Eye90 microspheres, a radiopharmaceutical breakthrough device manufactured on campus. The study aims to assess the safety and effectiveness of Eye90 in treating unresectable liver tumors, including hepatocellular carcinoma and metastatic colorectal cancer.
Researchers discovered that brief intermittent intense exercise is a more effective treatment for panic disorder than relaxation therapy. The 12-week program showed significant reductions in Panic and Agoraphobia Scale scores, anxiety, depression, and panic attack frequency and severity.
A ketogenic diet was found to have a modest effect in reducing depressive symptoms in patients with treatment-resistant depression. The study's results suggest that this dietary approach may be worth exploring as an adjunct therapy option.
A blind patient partially recovered natural vision through electrical stimulation of the visual cortex, independent of the implant. The recovery was sustained over time and remained even after the device was removed, suggesting individual factors may have contributed to this outcome.
Insilico Medicine received a USD 5 million milestone payment from Menarini Group after completing first-in-human dosing in a Phase 1 study of MEN2501, a small molecule inhibitor targeting cancers with chromosome instability. This achievement follows the completion of a successful Phase 1 clinical trial.
OYE-101, a novel intravenous caffeine formulation, aims to accelerate recovery from general anesthesia and deep sedation in adults. The FDA-cleared treatment also seeks to address opioid-induced respiratory depression and related overdose situations.
A recent study found that low-dose aspirin use was not associated with incident cancer incidence in older adults, contrary to previous findings. However, the study revealed a significant elevation in cancer mortality risk during the randomized clinical trial period, which did not persist after the trial ended.
A new MERS vaccine candidate has shown a stable and functional immune response in humans that persists for at least two years after a booster vaccination. The study demonstrates that such durable immunity can be achieved through targeted booster vaccinations, providing an important step toward an effective MERS vaccine.
A new study published in JAMA Network Open found that acupuncture is effective in reducing migraine without aura pain and improving functionality. The research identified specific brain network connections that predict treatment outcomes, enabling a personalized approach to pain management.
A large multinational clinical trial found that giving healthcare providers access to patient-reported outcome (PRO) data significantly improves the consistency of how treatment-related side effects are assessed in patients with cancer. This study highlights the importance of integrating the patient's voice into routine clinical evalua...